<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29947099</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1463-1326</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes, obesity &amp; metabolism</Title>
          <ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.</ArticleTitle>
        <Pagination>
          <StartPage>2598</StartPage>
          <EndPage>2607</EndPage>
          <MedlinePgn>2598-2607</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.13437</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">To compare the efficacy and safety of dapagliflozin and dapagliflozin plus saxagliptin vs glimepiride as add-on to metformin in patients with type 2 diabetes.</AbstractText>
          <AbstractText Label="RESEARCH DESIGN AND METHODS">This 52-week, multicentre, double-blind, active-controlled study (NCT02471404) randomized (1:1:1) patients (n = 939; HbA1c 7.5%-10.5%) on metformin monotherapy (≥1500 mg/day) to add-on dapagliflozin 10 mg, dapagliflozin 10 mg plus saxagliptin 5 mg, or glimepiride 1 to 6 mg (titrated). The primary efficacy end point was change in HbA1c from baseline to Week 52.</AbstractText>
          <AbstractText Label="RESULTS">Baseline mean age, diabetes duration and HbA1c were 58.4 years, 7.0 years and 8.3%, respectively. Adjusted mean HbA1c change from baseline was -1.20% with dapagliflozin plus saxagliptin and -0.82% with dapagliflozin, vs -0.99% with glimepiride (mean dose at Week 52, 4.6 mg). Changes in body weight (-3.2 kg and -3.5 kg vs +1.8 kg) and systolic blood pressure (SBP; -6.4 mm Hg and -5.6 mm Hg vs -1.6 mm Hg) were significantly greater with dapagliflozin plus saxagliptin and dapagliflozin than with glimepiride. FPG decreased significantly with dapagliflozin plus saxagliptin compared with glimepiride (-2.1 mmol/L vs -1.5 mmol/L) and was similar with dapagliflozin (-1.6 mmol/L) compared with glimepiride. Confirmed incidence of hypoglycaemia was lower with dapagliflozin regimens than with glimepiride (0 and 1 vs 13 patients) and fewer patients required rescue. Genital infections were more frequent with dapagliflozin; other AE profiles were similar.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Dapagliflozin, saxagliptin and metformin improved glycaemic control compared with glimepiride plus metformin; add-on of dapagliflozin alone showed efficacy similar to that of glimepiride. Both dapagliflozin regimens decreased body weight and SBP, with a lower incidence of hypoglycaemia compared with glimepiride.</AbstractText>
          <CopyrightInformation>© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Müller-Wieland</LastName>
            <ForeName>Dirk</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-8807-6442</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine I, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kellerer</LastName>
            <ForeName>Monika</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Marienhospital, Zentrum Innere Medizin I, Stuttgart, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cypryk</LastName>
            <ForeName>Katarzyna</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine and Diabetology, Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skripova</LastName>
            <ForeName>Dasa</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Outpatient Clinic of Diabetes and Metabolism, DIAMEL, Trencin, Slovakia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rohwedder</LastName>
            <ForeName>Katja</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, Wedel, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnsson</LastName>
            <ForeName>Eva</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca Gothenburg, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garcia-Sanchez</LastName>
            <ForeName>Ricardo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, Gaithersburg, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kurlyandskaya</LastName>
            <ForeName>Raisa</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca Gothenburg, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sjöström</LastName>
            <ForeName>C David</ForeName>
            <Initials>CD</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca Gothenburg, Mölndal, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacob</LastName>
            <ForeName>Stephan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Cardio-Metabolic Institute, Villingen-Schwenningen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seufert</LastName>
            <ForeName>Jochen</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-5654-7310</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dronamraju</LastName>
            <ForeName>Nalina</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, Gaithersburg, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Csomós</LastName>
            <ForeName>Katalin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>CRU Hungary Kft, Miskolc, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02471404</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Diabetes Obes Metab</MedlineTA>
        <NlmUniqueID>100883645</NlmUniqueID>
        <ISSNLinking>1462-8902</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005960">Glucosides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1ULL0QJ8UC</RegistryNumber>
          <NameOfSubstance UI="C529054">dapagliflozin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6KY687524K</RegistryNumber>
          <NameOfSubstance UI="C057619">glimepiride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9100L32L2N</RegistryNumber>
          <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001559" MajorTopicYN="N">Benzhydryl Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014552" MajorTopicYN="N">Urinary Tract Infections</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">DPP-IV inhibitor</Keyword>
        <Keyword MajorTopicYN="Y">SGLT2 inhibitor</Keyword>
        <Keyword MajorTopicYN="Y">dapagliflozin</Keyword>
        <Keyword MajorTopicYN="Y">phase III study</Keyword>
        <Keyword MajorTopicYN="Y">sulphonylureas</Keyword>
        <Keyword MajorTopicYN="Y">type 2 diabetes</Keyword>
      </KeywordList>
      <CoiStatement>D. M.‐W. is a member of speakers' bureaux and advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Merck Sharp &amp; Dohme, Novartis, Novo Nordisk and Sanofi. M. K. is a member of speakers' bureaux and advisory boards for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp &amp; Dohme, Novo Nordisk and Sanofi. K. C. has received honoraria and consulting fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Johnson &amp; Johnson, Novo Nordisk, Medtronic and Roche. D. S. has no conflicts of interest to disclose. K. R. is an employee of AstraZeneca. E. J., R. G.‐S., R. K. and C. D. S. are employees of and stockholders in AstraZeneca. S. J. has received honoraria, research support and consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol‐Myers Squibb, Daiichi Sankyo Inc., Janssen, Johnson &amp; Johnson, Lilly, Merck, Merck Sharp &amp; Dohme, Novartis, Novo Nordisk, Orexigen, Pfizer, Roche, Sanofi‐Aventis and Servier. J. S. has served on advisory boards and/or speakers' bureaux for Amgen, AstraZeneca, Bayer, Berlin‐Chemie, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Ipsen, Janssen, LifeScan, Merck, Merck Sharp &amp; Dohme, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi‐Aventis and Takeda; and has received research support from Amgen, Eli Lilly, GlaxoSmithKline, Intarcia, Ipsen, Janssen, Merck Sharp &amp; Dohme, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier and Takeda. N. Dronamraju is an employee of AstraZeneca. K. Csomós has no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29947099</ArticleId>
        <ArticleId IdType="pmc">PMC6220756</ArticleId>
        <ArticleId IdType="doi">10.1111/dom.13437</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
American Diabetes Association
. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(suppl 1):S1‐S132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient‐centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429‐442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25583541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fonseca VA, Kulkarni KD. Management of type 2 diabetes: oral agents, insulin, and injectables. J Am Diet Assoc. 2008;108:S29‐S33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18358251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm ‐ 2017 executive summary. Endocr Pract. 2017;23:207‐238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28095040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649‐1655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2732156</ArticleId>
            <ArticleId IdType="pubmed">19478198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add‐on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled 102‐week trial. BMC Med. 2013;11:43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3606470</ArticleId>
            <ArticleId IdType="pubmed">23425012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double‐blind, placebo‐controlled trial. Lancet. 2010;375:2223‐2233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20609968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kawalec P, Mikrut A, Lopuch S. The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. Diabetes Metab Res Rev. 2014;30:269‐283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24829965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes Obes Metab. 2011;13:65‐74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21114605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154‐1160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23906374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosenstock J, Hansen L, Zee P, et al. Dual add‐on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double‐blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376‐383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25352655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Evans JM, Ogston SA, Emslie‐Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930‐936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16525843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168:2070‐2080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2765722</ArticleId>
            <ArticleId IdType="pubmed">18955635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:938‐953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23594109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add‐on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‐week, double‐blind, active‐controlled noninferiority trial. Diabetes Care. 2011;34:2015‐2022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3161265</ArticleId>
            <ArticleId IdType="pubmed">21816980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nauck MA, Del Prato S, Duran‐Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16:1111‐1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24919526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Del Prato S, Nauck M, Duran‐Garcia S, et al. Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes Obes Metab. 2015;17:581‐590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25735400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosenstock J, Gross JL, Aguilar‐Salinas C, et al. Long‐term 4‐year safety of saxagliptin in drug‐naive and metformin‐treated patients with type 2 diabetes. Diabet Med. 2013;30:1472‐1476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23802840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cefalu WT, Leiter LA, Yoon K‐H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet. 2013;382:941‐950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23850055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add‐on to metformin in patients with type 2 diabetes: a 104‐week randomised, active‐controlled, double‐blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691‐700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24948511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sjostrom CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non‐hypertensive patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12:352‐358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26008804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamout H, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40:64‐74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25059406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853‐862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3906841</ArticleId>
            <ArticleId IdType="pubmed">23668478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sjostrom CD, Hashemi M, Sugg J, Ptaszynska A, Johnsson E. Dapagliflozin‐induced weight loss affects 24‐week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab. 2015;17:809‐812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25997813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703‐713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC28659</ArticleId>
            <ArticleId IdType="pubmed">9732337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mathieu C, Herrera Marmolejo M, Gonzalez Gonzalez JG, et al. Efficacy and safety of triple therapy with dapagliflozin add‐on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1134‐1137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27385192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mathieu C, Ranetti AE, Li D, et al. Randomized, double‐blind, phase 3 trial of triple therapy with dapagliflozin add‐on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009‐2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26246458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fadini GP, Bonora BM, Sarangdhar M, Rigato M, Avogaro A. DPP‐4 inhibitors moderate the risk of genitourinary tract infections associated with SGLT2 inhibitors. Diabetes Obes Metab. 2018;20:740‐744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29053207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644‐657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28605608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heerspink HJ, Johnsson E, Gause‐Nilsson I, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers. Diabetes Obes Metab. 2016;18:590‐597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4850750</ArticleId>
            <ArticleId IdType="pubmed">26936519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463‐473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3654568</ArticleId>
            <ArticleId IdType="pubmed">23464594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323‐334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27299675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shafiee G, Mohajeri‐Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012;11:17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3598174</ArticleId>
            <ArticleId IdType="pubmed">23497433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient‐reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health‐related quality of life. Diabetes Res Clin Pract. 2010;87:204‐210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20036433</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
